BACKGROUND Immunotherapy is a developing but challenging field of research for the
treatment of central nervous system malignancies. Chimeric antigen receptor (CAR)-T cell …

Chimeric antigen receptor (CAR)-T cell therapies are an undoubted success in childhood
acute lymphoblastic leukemia; however, this success has not translated clinically to any …

Background The dismal survival of glioblastoma (GBM) patients urgently calls for the
development of new treatments. Chimeric antigen receptor T (CAR-T) cells are an attractive …

Background: Pediatric high-grade gliomas (pHGGs) are aggressive brain tumors
responsible for significant childhood mortality. These tumors often carry mutations in the …

Nowadays, glioblastoma (GBM) was the most common and lethal form of primary
intracranial tumor. Despite standard-of-care therapy, GBM still exhibited a poor prognosis …

Glioblastoma (GBM) remains one of the most malignant primary tumors in adults, with a 5-
year survival rate less than 10% because of lacking effective treatment. Here, we aimed to …

Purpose: Patients with relapsed pediatric solid tumors and CNS malignancies have few
therapeutic options and frequently die of their disease. Chimeric antigen receptor (CAR) T …

Background Glioblastoma (GBM) is the most lethal form of primary brain tumor in adults, with
a 95% five-year mortality rate. Current therapy consists of surgical resection, chemotherapy …

Background Aggressive pediatric brain tumors such as atypical teratoid/rhabdoid tumor
(AT/RT), MYC-amplified medulloblastoma, high grade glioma and diffuse midline glioma are …

Background Immunotherapy with chimeric antigen receptor (CAR) T cells is actively being
explored for pediatric brain tumors in preclinical models and early phase clinical studies. At …